Compare ADM & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADM | RVMD |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4B | 30.1B |
| IPO Year | 2008 | N/A |
| Metric | ADM | RVMD |
|---|---|---|
| Price | $81.05 | $145.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | $64.00 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 3.7M | 2.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $80,269,000,000.00 | N/A |
| Revenue This Year | $4.80 | N/A |
| Revenue Next Year | $2.77 | $533.02 |
| P/E Ratio | $129.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $46.81 | $34.00 |
| 52 Week High | $83.10 | $155.70 |
| Indicator | ADM | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 66.38 | 57.13 |
| Support Level | $57.63 | $93.39 |
| Resistance Level | N/A | $152.38 |
| Average True Range (ATR) | 2.53 | 5.86 |
| MACD | 0.46 | -1.40 |
| Stochastic Oscillator | 79.86 | 46.61 |
Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.